Alkermes plc Q4 2025 Earnings Call Summary

2 weeks ago 9

Moby Intelligence

Wed, February 25, 2026 astatine 11:32 AM CST 4 min read

Management characterizes 2025 arsenic a pivotal year, transitioning from a royalty-based exertion institution to a proprietary products concern focused connected neuroscience and slumber medicine.
The acquisition of Avadel is described arsenic a strategical accelerator, providing an contiguous gross watercourse via LUMRIZE and a commercialized level for aboriginal orexin launches.
Performance successful the psychiatry franchise was attributed to a 2025 income unit expansion, which accrued telephone frequence and prescriber breadth for LYBALVI and ARISTADA.
Management views the orexin 2 receptor agonist portfolio arsenic a caller maturation vertical, with elixorexant positioned arsenic a imaginable blockbuster to beforehand the modular of attraction successful hypersomnia.
Operational efficiencies pursuing the merchantability of the Athlone manufacturing tract successful 2024 contributed to improved outgo of goods sold successful the existent period.
The institution is pivoting its R&D absorption toward 'translational' studies successful ADHD and fatigue, aiming to beryllium the orexin pathway's inferior beyond accepted slumber disorders.
CEO Richard Pops announced a enactment modulation to COO Blair Jackson for Summer 2026, citing the company's beardown fiscal presumption arsenic the rationale for the timing.

The 2026 gross guidance of $1.73B to $1.84B assumes a 10.5-month publication from LUMRIZE and reflects the phase-out of definite INVEGA royalties.
Phase 3 'Brilliance' programme for elixorexant successful narcolepsy is acceptable to initiate successful Q1 2026, utilizing a plan that includes some once-daily and split-dosing regimens.
Management expects to wage down the $1.525B word indebtedness utilized for the Avadel acquisition rapidly utilizing currency flows from the combined commercialized business.
Gross-to-net adjustments for LYBALVI are expected to widen into the mid-thirties successful 2026 arsenic portion of a strategical determination to grow payer entree and adoption.
R&D concern is projected to summation to $445M-$485M to enactment the initiation of Phase 3 narcolepsy trials and Phase 2 programs successful ADHD and fatigue.

A non-cash inventory step-up complaint of $150M related to LUMRIZE volition beryllium expensed successful 2026, importantly impacting GAAP results but not adjusted EBITDA.
VIVITROL and ARISTADA 2025 results included $27M and $14M respectively successful one-time gross-to-net favorability that absorption explicitly stated volition not recur successful 2026.
The expiration of Zeppelin royalties successful the 2nd fractional of 2026 is expected to make a headwind for manufacturing and royalty gross streams.
Management acknowledged imaginable generic contention for VIVITROL successful 2027, noting the product's manufacturing complexity arsenic a important obstruction to introduction for competitors.